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Abstract
Background: Autism spectrum disorder (ASD) is a complex developmental disorder characterised by impaired
social interaction and communication, and restrictive and repetitive behaviour. Previous systematic reviews have
traditionally assessed the prevalence of ASD on global or regional context, with very few meta-analyses at the
country level. The objective of this study will be to systematically evaluate published and unpublished observational
studies that present prevalence and comorbidity of ASD among children, adolescent and adult population in Spain.
Methods/design: We designed and registered a study protocol for a systematic review and meta-analysis of
descriptive epidemiology data. Observational studies (cohort, cross-sectional) reporting the prevalence of ASD and
conducted in a wide range of people (e.g. general population, outpatient and/or school settings) will be included.
The primary outcome will be the prevalence of ASD. Secondary outcomes will be the prevalence of any physical or
mental comorbidity in association with ASD. No limitations will be imposed on publication status, study conduct
period, and language of dissemination. Comprehensive literature searches will be conducted in seven electronic
databases (from January 1980 onwards), including PubMed/MEDLINE, EMBASE, Scopus, Web of Science, PsycINFO,
IME—Spanish Medical Index and IBECS—Spanish Bibliographic Index of Health Sciences. Grey literature will be
identified through searching dissertation databases, Google Scholar and conference abstracts. Two team members
will independently screen all citations, full-text articles, and abstract data. Potential conflicts will be resolved through
discussion. The study methodological quality (or bias) will be appraised using an appropriate tool. If feasible, we will
conduct random effects meta-analysis of observational data. Prevalence estimates will be stratified according to
gender, age and geographical location. Additional analyses will be conducted to explore the potential sources of
heterogeneity (e.g. methodological quality, sample size, diagnostic criteria).
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Discussion: This systematic review and meta-analysis of observational data will identify, evaluate and integrate the
epidemiological knowledge underlying the prevalence of ASD in Spain. The results of this study will be of interest
to multiple audiences including patients, their families, caregivers, healthcare professional, scientists and policy
makers. Results will be published in a peer-reviewed journal. Implications for future epidemiological research will be
discussed.
Systematic review registration: PROSPERO CRD42018090372
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Background
Autism spectrum disorder (ASD) is a complex develop-
mental disorder characterised by early-onset deficits in
social communication and reciprocal interactions as well
as the presence of restricted, stereotypical behaviour [1–
4]. ASD presents a set of behavioural problems that may
produce functional impairment in social, school, or work
performance and in the everyday activities of patients
and their families [1, 2, 5, 6]. Pathogenesis of the dis-
order is not completely understood, but there may be
many different causes that make a child more likely to
have an ASD, including genetic predisposition, environ-
mental and psychosocial factors [1–4].
The prevalence of ASD is now considered to be around
1% in many countries and regions worldwide [7–11], al-
though estimates of 2% have been suggested in some pub-
lished reports [7, 12]. Similar prevalence estimates have
been reported in adults [13, 14]. ASD seems to affect more
male than female individuals [15], and comorbidity is com-
mon (e.g. more than 50% may present concurrent physical
or mental conditions) [1, 16–21]. Most recent global bur-
den of disease estimates revealed 62.2 million people with
ASD around the world in 2016 [6].
Systematic reviews of epidemiological data (whether at a
national, regional or global levels) are important in the de-
scription of the geographical distribution of health prob-
lems [22, 23]. Systematic reviews of epidemiological data
can also identify gaps in knowledge and inform future
health care planning and research agendas [24]. Specific-
ally, they can be useful to get more precise estimates of
disease frequency, monitor trends and changes in disease
burden over time, and contribute to the design of further
studies (e.g. etiological and interventional studies). Previ-
ous systematic reviews and meta-analyses have tradition-
ally assessed the prevalence of ASD on global or regional
contexts [7, 8, 25–28], with very few examples of descrip-
tive epidemiology meta-analyses conducted at the country
level (e.g. India, China, Hong Kong and Taiwan) [29–31].
In recent years, several observational studies have been
conducted in different geographical locations and popu-
lation groups [7]. According to recent epidemiological
studies, in Spain, the prevalence of ASD would be 0.61%
in children aged 18months to 3 years in the Canary
Islands [32], 0.85% in children aged 0–14 years in Galicia
[33], 0.92% in children aged 18months to 3 years in
Castile-León [34], and 2% in samples of children aged
3–6 years in Catalonia [35]. To the best of our know-
ledge, no previous systematic reviews and meta-analyses
have evaluated ASD prevalence data in Spain. Therefore,
it would be relevant to identify, select, and critically ap-
praise the relevant epidemiological literature on ASD
and to collect and analyse data from studies through in-
tegrated and iterative approaches.
The objective of this study will be to systematically
evaluate published and unpublished observational epi-
demiological studies that present prevalence and comor-
bidity of ASD among children, adolescent and adult
population in a Southwestern European country: Spain.
Methods
Protocol
This study protocol is part of an ongoing evidence synthesis
project on the descriptive epidemiology and surveillance of
neurodevelopmental disorders [36]. The present protocol
has been registered within the PROSPERO database (regis-
tration number CRD42018090372) and is being reported in
accordance with the reporting guidance provided in the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses Protocols (PRISMA-P) statement [37, 38]
(see checklist in Additional file 1).
Information source and literature search
The primary source of literature will be a structured
search of seven major electronic databases (from January
1980 onwards—considering the Diagnostic and Statistical
Manual of Mental Disorders, Third Edition [DSM-III] was
published in 1980): PubMed/MEDLINE, EMBASE, Sco-
pus, Web of Science, PsycINFO, and also national data-
bases including IME—Índice Médico Español [Spanish
Medical Index] and IBECS–Índice Bibliográfico Español
en Ciencias de la Salud [Spanish Bibliographic Index of
Health Sciences]). The secondary source of potentially
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relevant material will be a search of the grey or difficult to
locate literature, including two dissertation databases
(TESEO—Base de datos de Tesis Doctorales [Spanish Data
Base of Doctoral Thesis Dissertations] and ProQuest Dis-
sertations and Theses Database), Google Scholar and con-
ference abstracts from selected national or local symposia
on mental health, neurology and paediatrics. We will per-
form hand-searching of the reference lists of included
studies, relevant reviews, national clinical practice guide-
lines or other relevant documents. Content experts and
authors who are prolific in the field will be contacted. The
literature searches will be designed and conducted by the
review team which includes two experienced health infor-
mation specialists. Our main literature search will be
peer-reviewed by a senior health information specialist
using the Peer Review of Electronic Search Strategies
(PRESS) checklist [39]. The search will include a broad
range of terms and keywords related to autism, epidemio-
logical studies and the geographical area ‘Spain’. For the
section of geographic area, the search will be based on a
previously validated filter to minimise potential bias re-
garding the indexing of geographical items [40]. This filter
is constructed around three complementary approaches:
(1) the term ‘Spain’ and its variants in various languages,
(2) terms related mainly to region and province place
names, and (3) acronyms for regional health services. A
draft search strategy for PubMed/MEDLINE is provided
in Additional file 2.
Eligibility criteria
Studies will be selected according to the following cri-
teria: participants, condition or outcome(s) of interest,
study design and context.
 Participants (population): We will include studies
involving children, adolescents and adult population
(regardless of age or sex).
 Condition or outcome(s) of interest: The primary
outcome will be the prevalence of ASD indicating
the number of people that have the disorder divided
by the population number at a given point in time.
This is often presented as a (prevalence) proportion.
In this study protocol, we use the term ‘autism
spectrum disorder’ to refer to both autistic disorder
(e.g. the ‘classic’ definition of autism) and ‘other
autism spectrum disorder combined’ (e.g. Asperger’s
disorder; pervasive developmental disorders not
otherwise specified, including atypical autism; Rett’s
disorder; and childhood disintegrative disorder) as
recommended elsewhere [7]. We will use author-
reported definitions (according to accepted diagnos-
tic criteria, such as the Diagnostic and Statistical
Manual of Mental Disorders (DSM) or the Inter-
national Classification of Diseases (ICD) criteria:
ICD-9: 299.00, 299.10, 299.80; ICD-10: F84). Sec-
ondary outcomes will be the prevalence of any co-
morbidity, indicating the existence of any distinct
additional (physical or mental) condition in associ-
ation with ASD (e.g. according to main DSM-IV or
ICD-10 categories of diagnoses).
 Study design and context: Eligible studies will be
observational studies (cohort, cross-sectional or
health surveys) reporting prevalence data using vali-
dated or non-validated tools and conducted in a
wide range of people in the Spanish general popula-
tion, outpatient (including data from administrative
databases and registries) and/or school settings.
Cross-sectional studies will be the most appropriate
study design to determine the prevalence of ASD.
Cross-sectional health surveys are typically used to
estimate the point prevalence of common conditions
of long duration and are generally less frequently
used for rare diseases such as ASD. For cohort stud-
ies, only the first phase (cross-sectional) data will be
considered. We will exclude studies in hospital/in-
patient clinical settings because they are likely to be
highly selected resulting in inaccurate estimations of
the ‘true prevalence’ of the disorder (selection bias).
No limitations will be imposed on publication status
(unpublished studies will be eligible for inclusion), study
conduct period, and language of publication.
Screening and selection procedure
All articles identified from the literature search will be
screened by two team members independently. First, titles
and abstracts of articles returned from initial searches will
be screened based on the eligibility criteria outlined above.
Second, full texts will be examined in detail and screened
for eligibility. Third, references of all considered articles will
be hand-searched to identify any relevant report missed in
the search strategy. Any disagreements will be resolved by
discussion to meet a consensus, if necessary. A flow chart
showing details of studies included and excluded at each
stage of the study selection process will be provided [41].
Data collection
A data extraction form will be designed and used to ex-
tract equivalent information from each study report. In-
formation of interest will include the following:
 Study characteristics: study design, year of
publication, journal, year (or period) of study
conduct, sample size, setting (community, school or
outpatient), geographical location of study conduct:
North (Galicia, Asturias, Cantabria, Aragon, Basque
Country, Navarre, La Rioja), Mediterranean
(Balearics, Catalonia, Valencia), Centre (Castile-La
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Mancha, Castile-León, Madrid, Extremadura), and
South-East (Andalusia, Murcia and Canary
Islands); and other fields to capture data relevant
to the assessment of study methodological quality
(see risk of bias and methodological quality as-
sessment subsection).
 Participant characteristics: population sampled, age
(e.g. mean with standard deviation, range) and
gender (e.g. percentage of female participants).
 Outcome results: definitions and assessment tools
(e.g. DSM-III, DSM-IV, ICD-9, ICD-10, other), data
collection method (e.g. self-complete, questionnaire,
interview and examination, clinical records), preva-
lence estimates (e.g. number of subjects with the dis-
order, proportion and 95% confidence interval) and
any prevalence estimates stratified by age, gender,
severity or location. If outcome results (e.g. propor-
tion and 95% confidence interval) are not directly
provided and it is feasible, we will calculate them
from the number of cases and sample size provided
in each single study.
Data extraction forms will be piloted initially on a
small number of included studies. Subsequently, each of
the included studies will be abstracted by two team
members, independently, and potential conflicts will be
resolved through discussion. Authors of primary publi-
cations will be contacted for data clarifications or miss-
ing outcome data, as necessary.
Risk of bias and methodological quality assessment
The risk of bias of primary observational studies will be
evaluated using a methodological quality critical ap-
praisal checklist proposed in the Joanna Briggs Institute
(JBI) systematic review methods manual [42, 43]. This
methodological quality checklist for observational stud-
ies reporting prevalence data considers: sample repre-
sentativeness, recruitment appropriateness, sample size,
description of subjects and setting, coverage of data ana-
lysis, ascertainment and measurement of the condition,
thoroughness of reporting statistical analysis, and identi-
fication and accountability of potential confounding fac-
tors/subgroups (see Additional file 3). We will provide a
narrative summary of the risk of bias of the included
studies, which will be supported by a table showing the
results of the critical appraisal. Stars or points will be
awarded for each quality item, and the highest quality
studies will be awarded up to ten stars. Studies will be
judged to be at low risk of bias (≥ 7 points), moderate
risk of bias (4–6 points) or high risk of bias (< 4 points).
The risk of bias for each observational study will be in-
dependently assessed by two reviewers. Discrepant
scores will be resolved by discussion and consensus.
Methods for evidence synthesis
The data from each paper (e.g. study characteristics,
context, participants, outcomes and findings) will be
used to build evidence tables of an overall description of
included studies. Crude prevalence estimates (number of
cases/sample size) will be presented along with 95% con-
fidence intervals.
If feasible and appropriate, prevalence data points from
primary observational studies will be used to perform ran-
dom effects meta-analyses. Since heterogeneity is expected
a priori, we will estimate the pooled prevalence and its
95% confidence interval using the random effects model
with logit transformation and back transformation as rec-
ommended elsewhere [8, 22]. The random effects model
assumes the study prevalence estimates follow a normal
distribution, considering both within-study and between-
study variation. Forest plots will be used to visualise the
extent of heterogeneity among studies. Prevalence esti-
mates will be expressed as cases per 10,000 people [8, 31].
We will quantify statistical heterogeneity by estimating
the variance between studies using I2 statistic [44]. The
I2 is the proportion of variation in prevalence estimates
that is due to genuine variation in prevalence rather than
sampling (random) error. I2 ranges between 0% and
100% (with values of 0–25% and 75–100% taken to indi-
cate low and considerable heterogeneity, respectively).
We will also report Tau2 [45] and Cochran Q test [46]
with a P value of < 0.05 considered statistically signifi-
cant (heterogeneity).
Additional analyses
If sufficient studies are identified and data points are avail-
able, potential sources of heterogeneity will be investigated
further by subgroup or meta-regression analyses accord-
ing to baseline characteristics and methodological covari-
ates. We plan to conduct analyses by gender (male vs
female), age (e.g. children vs adolescent vs adult, mid-
point of age range as continuous variable), severity (e.g.
mild, moderate or severe), geographical location (e.g.
North, Mediterranean, Centre and South-East), setting
(e.g. community/school vs outpatient), sample size (e.g. <
1000, 1000–5000 or > 5000 participants), decade of publi-
cation (e.g. 1990, 2000 or 2010), study quality (e.g. low/
moderate vs high-risk of bias), autism definition (e.g. aut-
istic disorder vs other autism disorders combined), diag-
nostic system (e.g. DSM vs ICD criteria) and most recent
diagnostic criteria (e.g. ‘DSM-IV or ICD-10’ vs ‘Not DSM-
IV or ICD-10’). In addition, we will explore prevalence
trends with gender variations (in terms of the female-to-
male prevalence ratios) [15] and over time (with the year
of publication as the explanatory variable) [1] using ran-
dom effects meta-regression models [47]. Small study ef-
fects will be assessed by inspection of the funnel plots for
asymmetry and with Egger’s test [48] and Begg’s test [49],
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with the results considered to indicate potential small
study effects when P values < 0.10.
Software considerations
All analyses will be conducted in Stata version 15 (Stata-
Corp LP, College Station, Texas, USA) [50, 51].
Ethics, dissemination and research integrity
No ethical approval is required for the performance of this
study. The proposed systematic review and meta-analysis
will be reported in accordance with the reporting guidance
provided in the Preferred Reporting Items for Systematic
Reviews and Meta-analyses (PRISMA) statement [41] and
the Meta-analysis Of Observational Studies in Epidemi-
ology (MOOSE) reporting guideline [52]. Any amend-
ments made to this protocol when conducting the study
will be outlined and reported in the final manuscript. Re-
sults will be disseminated through conference presenta-
tions and publication in a peer-reviewed journal. All data
underlying the findings reported in the final manuscript
will be deposited in a cross-disciplinary public reposi-
tory—for example, the Open Science Framework (https://
osf.io/) or Zenodo (https://zenodo.org/).
Patient and public involvement
One of the study protocol co-authors (AT) is the parent
of a child with ASD and a member of a patient group
(APRENEM Association for the Inclusion of People with
ASD, Barcelona, Spain). We will evaluate whether the
epidemiological studies included in the systematic review
had any patient and/or public involvement [53, 54].
Discussion
The systematic review and meta-analysis of observational
data presented in this protocol will identify, collect, evalu-
ate and integrate the epidemiological knowledge under-
lying the prevalence of ASD in Spain. We are not aware of
another systematic review and meta-analysis addressing
this specific issue. In our opinion, this systematic review
will help to establish the extent of the epidemiological evi-
dence on ASD at a country level, in a reproducible and
rigorous way.
The results of this study will be of interest to multiple
audiences (including patients, their families, caregivers,
healthcare professionals, researchers, scientists and deci-
sion makers). For example, the National Plan for Autism
was issued in 2015 to develop specific measures to im-
prove quality of life, promote awareness and identify and
respond to the needs of those living with ASD [55]. The
National Plan considered several strategic lines in terms of
diagnosis, integrated care, health care, education, employ-
ment and research, among others. However, routine popu-
lation estimates of ASD prevalence (based on the most
updated systematic literature reviews) are not reported
[55, 56]. Outputs of this analysis could be relevant to
current policy questions.
There are several strengths and limitations of our
planned systematic review methods. We will comprehen-
sively evaluate epidemiological data (both published and
unpublished) characterising the prevalence and comorbidity
of ASD, exploring the extent of heterogeneity and potential
biases in observational studies. We anticipate that we will
identify knowledge gaps to be filled by new epidemiological
research considering that the prevalence of neurodevelop-
mental disorders has been poorly covered in the literature
[7, 57]. On this regard, implications for future epidemio-
logical research will be discussed in the final manuscript. A
key challenge is that based on knowledge from previous re-
views on child mental health [7, 8, 25, 31, 57–59], we antici-
pate identifying studies using different study designs,
populations, contexts and with a variable quality of report-
ing methods and results.
Finally, the availability of country-specific prevalence es-
timates of ASD over time will provide opportunities to
undertake systematic assessments of the burden of disease
and to promote evidence-based policy action [6, 60–62].
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